The present work
describes the development and characterization
of liquid crystalline nanoparticles of hispolon (HP-LCNPs) for treating
hepatocellular carcinoma. HP-LCNPs were prepared by a top-down method
utilizing GMO as the lipid and Pluronic F-127 as the polymeric stabilizer.
The prepared formulations (HP1–HP8) were tested for long-term
stability, where HP5 showed good stability with a particle size of
172.5 ± 0.3 nm, a polydispersity index (PDI) of 0.38 ± 0.31
nm, a zeta potential of −10.12 mV ± 0.05, an entrapment
efficiency of 86.81 ± 2.5%, and a drug loading capacity of 12.51
± 1.12%. Optical photomicrography and transmission electron microscopy
images demonstrated a consistent, low degree of aggregation and a
spherical shape of LCNPs. The effect of temperature and pH on the
optimized formulation (HP5) indicated good stability at 45 °C
and at pH between 2 and 5. In vitro gastrointestinal stability indicated
no significant change in the particle size, PDI, and entrapment efficiency
of the drug. The drug release study exhibited a biphasic pattern in
simulated gastric fluid (pH 1.2) for 2 h and simulated intestinal
fluid (pH 7.4) for up to 24 h, while the best fitting of the profile
was observed with the Higuchi model, indicating the Fickian diffusion
mechanism. The in vivo pharmacokinetic study demonstrated nearly 4.8-fold
higher bioavailability from HP5 (AUC: 1774.3 ± 0.41 μg*
h/mL) than from the HP suspension (AUC: 369.11 ± 0.11 μg*
h/mL). The anticancer activity evaluation revealed a significant improvement
in antioxidant parameters and serum hepatic biomarkers (SGOT, SGPT,
ALP, total bilirubin, and GGT) in the diethyl nitrosamine-treated
group of rats with the optimized LCNP formulation (HP5) vis-à-vis
HP suspension.